利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.027 秒)

    Peptide compositions and their use against HCV
    3.
    发明授权
    Peptide compositions and their use against HCV 失效
    肽组合物及其对HCV的用途

    公开(公告)号：US07393831B2

    公开(公告)日：2008-07-01

    申请号：US10514762

    申请日：2003-05-15

    申请人： Anne Fournillier ,  Nourredine Himoudi ,  Geneviève Inchauspe

    发明人： Anne Fournillier ,  Nourredine Himoudi ,  Geneviève Inchauspe

    IPC分类号： A61K39/02 ,  A61K39/29 ,  A61K39/42 ,  A61P31/00 ,  C07K14/18 ,  C07K14/195 ,  C07K16/10

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C12N2770/24222

    摘要： The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, a peptide D having at least the amino acid sequence of SEQ. ID No174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

    摘要翻译： 本发明涉及新型肽组合物。 特别地，本发明涉及包含至少两种选自以下肽的肽的肽组合物：至少具有SEQ ID NO：1的氨基酸序列的肽A，肽 B至少具有SEQ ID NO：45的氨基酸序列，至少具有SEQ ID NO：127的氨基酸序列的肽C，肽D具有 至少SEQ ID NO：1的氨基酸序列。 174 N。 本发明的组合物特别可用于制备抗丙型肝炎病毒的活性药物组合物。

    Peptide compositions and their use against the hepatitis C virus
    5.
    发明授权
    Peptide compositions and their use against the hepatitis C virus 失效
    肽组合物及其对丙型肝炎病毒的应用

    公开(公告)号：US08080525B2

    公开(公告)日：2011-12-20

    申请号：US12132321

    申请日：2008-06-03

    申请人： Anne Fournillier ,  Nourredine Himoudi ,  Genevieve Inchauspe

    发明人： Anne Fournillier ,  Nourredine Himoudi ,  Genevieve Inchauspe

    IPC分类号： A61K39/02 ,  A61K39/29 ,  A61K39/42 ,  A61P31/00 ,  C07K14/18 ,  C07K14/195 ,  C07K16/10

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C12N2770/24222

    摘要： Novel peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

    摘要翻译： 描述了新的肽组合物。 特别地，描述了肽组合物，其包括至少两种选自以下肽的肽：至少具有SEQ ID NO 1的氨基酸序列的肽A，至少具有SEQ ID NO 1的氨基酸序列的肽B ID NO 45，至少具有SEQ ID NO 127的氨基酸序列的肽C和至少具有SEQ ID NO 174的氨基酸序列的肽D.该组合物特别可用于制备 针对丙型肝炎病毒的活性药物组合物。

    Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus
    8.
    发明申请
    Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus 失效
    新型肽组合物及其用途，特别是制备抗丙型肝炎病毒的活性药物组合物

    公开(公告)号：US20090075879A1

    公开(公告)日：2009-03-19

    申请号：US12132321

    申请日：2008-06-03

    申请人： Anne Fournillier ,  Nourredine Himoudi ,  Genevieve Inchauspe

    发明人： Anne Fournillier ,  Nourredine Himoudi ,  Genevieve Inchauspe

    IPC分类号： A61K38/16

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C12N2770/24222

    摘要： The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, and a peptide D having at least the amino acid sequence of SEQ ID No 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

    摘要翻译： 本发明涉及新型肽组合物。 特别地，本发明涉及包含至少两种选自以下肽的肽的肽组合物：至少具有SEQ ID No1的氨基酸序列的肽A，具有至少氨基酸序列的肽B SEQ ID No45，至少具有SEQ ID No127的氨基酸序列的肽C和至少具有SEQ ID No 174的氨基酸序列的肽D.本发明的组合物特别可用于制备 针对丙型肝炎病毒的活性药物组合物。